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Because substance p (SP) has been reported to be
released from cutaneous sensory nerve endings after
hapten application, we determined whether SP
participates in contact hypersensitivity (CH) induc-
tion by using a SP agonist, GR73632 or d-Aminova-
leryl [Pro9, N-Me-Leu10]-substance P7–11 and a SP
antagonist, spantide I. When injected intradermally,
SP agonist enhanced CH induced by conventional,
but not optimal, sensitizing doses of hapten. By
contrast, SP antagonist inhibited the induction of
CH by optimal sensitizing doses of hapten. Moreover,
SP agonist promoted CH induction and prevented
tolerance when hapten was painted on skin exposed to
acute, low-dose ultraviolet-B radiation. Intradermally
Exposure of murine skin to ultraviolet B radiation (UVR)causes profound changes in local (cutaneous) and sys-temic immunity (Kripke, 1984; Streilein, 1993). Ourlaboratory has used an acute, low-dose UVR protocoldirected at the shaved body wall skin of mice to study
the deleterious effects of UVR (Toews et al, 1980). When a
sensitizing dose of hapten, such as dinitrofluorobenzene (DNFB),
is painted on the irradiated surface immediately after the last of
four consecutive daily UVR exposures, contact hypersensitivity
(CH) fails to develop in certain genetically defined strains of mice,
termed UVB-susceptible, but CH develops in other mice, termed
UVB-resistant (Streilein and Bergstresser, 1988; Yoshikawa and
Streilein, 1990; Kurimoto and Streilein, 1993). If the hapten is
painted on a cutaneous site distant from the original site of UVR
rather than on the exposed site, CH develops normally in UVB-
susceptible mice, indicating that the primary immune defect created
by UVR in this protocol is at the irradiated site (Shimizu and
Streilein, 1994b). Moreover, when sensitizing doses of the hapten
are painted simultaneously on UVR-exposed and unexposed skin,
shortly after the last dose of UVR, normal levels of CH are induced
(Shimizu and Streilein, 1994b). This result considerably strengthens
the conclusion that acute, low-dose UVR impairs CH induction
by a strictly local action. It has been proposed that the ‘‘strictly
local’’ effects of acute, low-dose UVR on CH induction are
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injected SP agonist altered neither the density nor
the morphology of epidermal Langerhans cells,
implying that SP agonist enhanced the generation
of hapten-specific immunogenic signals from the
dermis. It is proposed that SP is a natural ‘‘adjuvant’’
that promotes the induction of CH within normal
skin. Although exogenous SP agonist can prevent
impaired CH and tolerance after ultraviolet-B radi-
ation, the susceptibility of native SP to local
neuropeptidases renders the neuropeptide unable to
prevent the deleterious effects of ultraviolet-B radi-
ation on cutaneous immunity. Key words: contact
hypersensitivity/neuroimmunology/tolerance/suppression. J
Invest Dermatol 112:437–442, 1999
mediated primarily by tumor necrosis factor (TNF)-α (Yoshikawa
and Streilein, 1990; Shimizu and Streilein, 1994b).
We recently reported that calcitonin gene-related peptide
(CGRP) is central to the deleterious effect on CH induction, and
that CGRP acts via a TNF-α dependent mechanism in UVB-
susceptible mice (Niizeki et al, 1997). We hypothesized that UVR
stimulates nerve endings to release CGRP, which triggers dermal
mast cells to secrete TNF-α (Niizeki et al, 1997). Although
cutaneous sensory nerve endings secrete substance p (SP) simultan-
eously with CGRP if stimulated (reviewed in Ansel et al, 1996),
the possible roles of SP on CH induction are presently unknown.
SP, a neuropeptide of the tachykinin family, exerts several
biologic activities in the central nervous system and in peripheral
organs, mainly (but not exclusively) as a neurotransmitter and
neuromodulator (reviewed in Ansel et al, 1996). SP is also known
to modulate certain parameters of the immune response, including
proliferation (Payan et al, 1984) and IL-2 production by T cells
(Calvo et al, 1992; Rameshwar et al, 1993). SP inhibits hapten-
specific IgE production (Carucci et al, 1994). In addition, SP
modifies cytokine gene expression and eicosanoid production of
macrophages/monocytes (Kimball et al, 1988; Lotz et al, 1988;
Laurenzi et al, 1990; Murris-Espin et al, 1995), and alters tumoricidal
function (Peck, 1987), chemotaxis (Ruff et al, 1985), phagocytosis
(Bar-Shavit et al, 1980), and induction of oxidative burst and
thromboxane release (Hartung and Toyka, 1983) by IFN-γ activated
macrophage. Recently, it was reported that a SP agonist stimulates
the production of IL-12 by lipopolysaccharide-activated macro-
phages (Kincy-Cain and Bost, 1997).
SP is a highly unstable neuropeptide when injected into living
tissues, presumably because it is sensitive to indigenous neuro-
peptidases (Matsas et al, 1984). Therefore, in order to study the
potential role of SP in vivo we chose the SP agonist (GR73632
or δ-Aminovaleryl [Pro9, N-Me-Leu10]-substance P7–11). This
molecule is quite stable when injected in vivo, and is a potent and
selective agonist for neurokinin-1 receptors (NK-1R) (Hagan et al,
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1989). Here we show that signals delivered through the SP receptor
(NK-1R) enhance CH induction on normal skin and overwhelm
the deleterious effects of UVR on cutaneous immunity.
MATERIALS AND METHODS
Mice Adult mice, aged 8–12 wk, of C3H/HeN inbred lines were
purchased from Taconic Farms (Germantown, NY). All animal procedures
were approved by the institutional Animal Care and Use Committee.
Experimental procedures were carried out with the animals under general
anesthesia achieved by intraperitoneal injection of ketamine (12.5 mg per
ml; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (0.125 mg per
ml; Phoenix Pharmaceutical, St. Joseph, MO). Each control or experimental
panel consisted of five mice. Each experimental protocol was repeated at
least twice with similar results.
Reagents DNFB (2, 4-dinitro-1-fluorobenzene) and oxazolone
(4-ethoxymethylene-2-phenyloxazol-5-one) were purchased from Sigma
(St. Louis, MO). SP agonist (GR73632 or δ-Aminovaleryl [Pro9,
N-Me-Leu10]-substance P7–11 11) and spantide I, a substance p antagonist
([D-Arg1, D-Trp7,9, Leu11]-substance p) was purchased from Peninsula Lab
(Belmont, CA). Peptides were stored at 1 mg per ml in distilled water at
–70°C. Anti-Iak antibody and fluoroscein isothiocyanate-conjugated goat
anti-mouse antibody were purchased from Becton Dickinson (Mountain
View, CA) and CAPPEL (Durham, NC), respectively.
Intradermal (i.d.) injections Using a 1.0 ml syringe with a 30 gauge
needle, the contents of the syringe were placed within the i.d. space.
Successful inoculations were characterized by the appearance of a flattened
swelling with defined lateral margins immediately beneath the epidermis
(Niizeki and Streilein, 1997).
Identification and enumeration of epidermal Langerhans
cells Epidermis was separated from dermis by incubation in ethylenediam-
inetetraacetic acid. Langerhans cells in these epidermal sheets were stained
with monoclonal anti-Ia antibody as described previously (Bacci et al,
1996), and evaluated under epifluorescent microscopy. With the aid of an
eyepiece with a 1 mm2 grid, a minimum of 10 fields was counted for each
sample to enumerate the number of positively stained cells and to calculate
the mean number of stained cells per mm2 epidermis.
Induction and expression of CH Twenty-five microliters of 0.5%
(185 µg) or 0.004% (1.5 µg) DNFB in acetone was applied to the dry-
shaved abdominal cutaneous surface of mice on day 0 (Kurimoto and
Streilein, 1993; Bacci et al, 1997). CH was elicited on day 5 by challenging
one ear of each mouse with 20 µl of 0.05% DNFB. Ear swelling was
measured with an engineer’s micrometer (Mitutoyo, Tokyo, Japan) 24 h
and 48 h following challenge and compared with ear thickness prior
to challenge.
Assessment of tolerance DNFB in acetone (185 µg) was applied to
dry-shaved abdominal skin on day 0. Two weeks later, the same mice
received a second epicutaneous application of DNFB in acetone (185 µg)
on previously untreated, dry-shaved dorsal body wall skin (Niizeki and
Streilein, 1997). The ears of these mice were challenged 5 d later and ear
thicknesses were measured as described above.
UVR Shaved abdominal skin was exposed to UVB from a bank of four
FS-20 fluorescent lamps with a tube-to-target distance of 46 cm as
previously described (Niizeki and Streilein, 1997). These bulbs have a
broad emission spectrum (250–400 nm) and high output primarily in the
UVB range (290–320 nm). As measured by an IL 700 radiometer with a
SEE 240 UVB photodetector (Medko Medical Instrumentarium, Finland),
these lamps delivered an average flux of 1.4 per m2 per s. Mice were
exposed to UVB daily for four consecutive days (400 J per m2 per day)
on the abdominal cutaneous surface.
Statistical analysis The statistical significance of differences between
means of each experimental group was determined with analysis of variance.
Mean differences were considered to be significant when p , 0.05. Analyses
were performed using StatView 5121 (Abacus Concepts, Berkeley, CA)
on a Macintosh IIci microcomputer.
RESULTS
SP agonist fails to alter epidermal Langerhans cells We
have reported that CGRP, a neuropeptide present in c-type nerve
terminii of the epidermis, can decrease the density of epidermal
Table I. SP agonist fails to alter the density of epidermal
Ia1 cellsa
Number of Ia1 cells 6 SEM per mm2
PBS 699.2 6 37
SP agonist 739 6 48
UVB 1 PBS 550.4 6 35*
UVB 1 SP agonist 500.8 6 31**
aC3H/HeN mice received intradermal injections of PBS or SP agonist (5 nmol)
on dry-shaved abdominal skin. In some mice, 400 J UVB per m2 of radiation was
delivered to the injection site within 30 min. Two hours after the injections,
epidermal sheets were prepared from injected sites (26). Asterisks indicate values
significantly lower than PBS (positive control): *p , 0.05, **p , 0.001.
Langerhans cells via a TNF-α-dependent mechanism when CGRP
is injected intradermally (Niizeki et al, 1997). Because SP is
coexpressed with CGRP in cutaneous sensory nerves (reviewed in
Ansel et al, 1996), we first wished to know whether SP can also
alter the density of epidermal Langerhans cells. Rather than using
SP itself, which is highly labile, we turned to a substance p agonist
that bears a striking resemblance to native SP, and binds the SP
receptor (NK-1R) with high affinity (Hagan et al, 1989). The dose
of SP agonist used in the following experiments was chosen
according to the experience reported by Yano et al (1989). These
investigators reported that five nanomoles of SP is capable of
evoking ear swelling when injected intrapinnally into mice (Yano
et al, 1989).
C3H/HeN mice received i.d. injections of 5 nmol of SP agonist
[or phosphate-buffered saline (PBS) as positive control] into shaved
abdominal skin. Two hours later, biopsies were taken and epidermal
sheets were prepared as described previously (Bacci et al, 1996).
Cells positive for Ia antigens were enumerated with 10 mm grid.
The epidermis of SP agonist-treated mice displayed a similar density
of Ia1 Langerhans cells as compared with epidermis after PBS
injection (Table I). These data suggest that SP agonist has no effect
on the density of epidermal Langerhans cells. In companion
experiments SP agonist failed to reverse the deleterious effects of
UVR on Langerhans cells density (Table I). These findings are
consistent with our previous report that a CGRP antagonist is able
to prevent Langerhans cells depletion by UVR, even though both
SP and CGRP are presumed to be released from cutaneous nerve
endings after UVR (Niizeki et al, 1997).
SP agonist augments the induction of CH We next wished
to determine whether SP agonist can augment the induction of
CH when hapten is painted on normal skin. Panels of C3H/HeN
mice received i.d. injections of 5 nmol of SP agonist. Positive
control mice received i.d. injections of PBS. Within 30 min, a
conventional sensitizing dose of DNFB (185 µg in acetone) was
carefully applied directly on the skin overlying the injection sites.
Five days later, the ear pinnae of these mice, along with unsensitized
negative controls, were challenged with dilute DNFB (15 µg in
acetone). The ear swelling responses at 24 h (in one of two
experiments) are presented in Fig 1(A). The intensity of ear
swelling measured in ears of mice that received i.d. injection of SP
agonist was significantly greater than that of positive controls (only
PBS injected). These results indicate that 5 nmol of SP agonist
augments CH induction. A dose response experiment was con-
ducted in which different doses of SP agonist (0.05, 0.5, and
5 nmol) were injected prior to application of DNFB (185 µg).
Only the 5 nmol dose of SP agonist was capable of enhancing CH
induction (data not shown). In a subsequent set of experiments,
SP agonist was injected i.d. into C3H/HeN mice and thereafter
an optimal sensitizing dose of DNFB (1.5 µg) was applied to the
site. Control mice received i.d. injections of PBS. When the ears
of these mice were challenged with dilute DNFB 5 d later, the
intensity of ear swelling was virtually identical in both groups of
mice (Fig 1B). These findings reveal that SP agonist is capable of
augmenting the intensity of CH induction if hapten is applied at
conventional sensitizing doses, but not if optimal sensitizing doses
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Figure 1. SP agonist can enhance CH
induction. C3H/HeN mice received
epicutaneous application of DNFB (A,
185 µg; B, 1.5 µg) to abdominal sites
previously injected with SP agonist
(5 nmol). Five days later, their ears were
challenged with DNFB (15 µg). Ear
swelling responses at 24 h are presented as
mean 6 SEM (µm). Mean values
significantly higher than positive control:
*p , 0.00001.
Figure 2. Spantide I (SP antagonist) impairs CH induction. C3H/
HeN mice received an epicutaneous application of DNFB (1.5 µg) to
abdominal skin sites into which spantide I (5 nmol) had been injected
30 min previously. Five days later, ears were challenged with DNFB
(15 µg). Ear challenge and the determination of ear swelling responses are
presented as described in the legend to Fig 1. Mean values significantly
lower than positive control: *p , 0.0005.
of hapten are applied. There is circumstantial evidence (Kurimoto
and Streilein, 1993; Bacci et al, 1997) that optimal sensitizing doses
of hapten rely almost exclusively upon epidermal antigen-presenting
cell (APC), whereas conventional doses of hapten diffuse well into
the dermis and actually relay primarily on dermal APC for CH
induction. These findings have led us to postulate that SP augments
CH induction by enhancing the activities of dermal, rather than
epidermal, APC.
A SP antagonist, spantide, impairs CH induction Although
5 ng of SP agonist was incapable of enhancing CH induction with
optimal sensitizing doses of hapten (Fig 1B), we considered the
possibility that under physiologic conditions sufficient SP is released
to promote CH induction at this low level of hapten dose. To test
for this possibility, we tested a SP antagonist, spantide I, for its
capacity to impair CH induction when an optimal sensitizing dose
of hapten was applied epicutaneously. Panels of C3H/HeN mice
were subjected to intradermal injection of 5 ng spantide I (or PBS
alone) before sensitization. Within 30 min, DNFB (1.5 µg) was
painted on the injected site (Bacci et al, 1997). The ears of these
mice were challenged with DNFB (15 µg) 5 d later and the ear
swelling responses were measured at 24 h. The results of a
representative experiment (of two) are displayed in Fig 2. Mice
that received intradermal injections of spantide immediately prior
to hapten application displayed impaired CH when compared with
PBS-injected mice (positive control). This result supports the view
that SP released from cutaneous nerves participates in the process
by which CH is induced in mice – using either optimal or
conventional sensitizing doses of hapten.
SP agonist promotes CH induction by a local effect We
wished next to know whether SP agonist acted locally or systemic-
ally to augment induction of CH. Panels of C3H/HeN mice
received i.d. injection of 5 nmol SP agonist into abdominal skin
Figure 3. SP agonist enhances CH induction via a local effect.
C3H/HeN mice received an i.d. injection of SP agonist (5 nmol) into
abdominal skin. Within 30 min, DNFB (185 µg) was painted either on
the abdominal site of injection (Group 2), or on dorsal (uninjected) skin
(Group 1). Control mice received abdominal skin injection of PBS (Group
3). Ear challenge and determination of ear swelling responses are presented
as described in the legend to Fig 1. Mean values significant higher than
positive control (Group 3): *p , 0.001.
(Group 2), or dorsal body wall skin (Group 1). Positive control
mice received i.d. injections of PBS on abdominal skin (Group 3).
Within 30 min, DNFB (185 µg) was applied to abdominal skin of
all three groups of mice. Five days later, the ear pinnae were
challenged with 15 µg DNFB. The results of a representative
experiment (one of two) are presented in Fig 3. Mice that first
encountered DNFB via SP agonist-injected skin displayed enhanced
CH, whereas mice that first encountered DNFB via uninjected
skin (these mice received SP agonist injections into dorsal skin)
displayed CH comparable in intensity to positive controls. Thus,
the capacity of SP to enhance CH induction is expressed locally,
at the site of SP agonist injection, not at a distance (i.e., systemically).
SP agonist prevents UVR-impaired CH Because SP agonist
can augment CH induction in normal, unperturbed skin, we
wondered whether SP agonist might also be capable of preventing
the impaired CH that follows exposure to acute, low-dose UVR.
To test this possibility, panels of C3H/HeN mice received four
consecutive daily dose of acute, low-dose UVR. Immediately after
the last exposure, mice received i.d. injections of 5 nmol of SP
agonist or PBS (UVR controls). Within 30 min, DNFB (185 µg
in acetone) was applied directly on the skin overlying the injection
sites. Five days later, the ear pinnae of these mice, along with
unsensitized negative controls, were challenged with dilute DNFB
(15 µg in acetone). The 24 h ear swelling responses of C3H/HeN
mice (in one of two experiments) are presented in Fig 4. The
intensity of ear swelling measured in ears of mice that received i.d.
injection of PBS after UVR was significantly less than that of
positive control (no UVR exposure); however, mice that received
i.d. injections of SP agonist after UVR displayed ear swelling
responses virtually identical to positive controls. Thus, SP can
prevent impaired induction of CH after acute, low-dose UVR.
SP agonist can prevent induction of UVR-dependent
tolerance We next examined the possibility that 5 nmol of
i.d.-injected SP agonist could prevent the development of hapten-
specific tolerance as has been reported for UVR (Toews et al, 1980;
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Figure 4. SP agonist reverses the deleterious effect of UVR on CH
induction. Abdominal skin of C3H/HeN mice received exposure to
400 J UVR per m2 daily for four consecutive days. Immediately after the
last exposure, SP agonist was injected intradermally into the exposed sites.
Within 30 min after injections, DNFB (185 µg) was applied to the injected
surface. Ear challenge and the determination of ear swelling responses are
presented as described in the legend to Fig 1. Mean values significantly
lower than positive control (Group 4): *p , 0.00001.
Figure 5. SP agonist prevents induction of tolerance after UVR.
Abdominal skin of C3H/HeN mice received exposure to 400 J UVR per
m2 daily for four consecutive days. Within 30 min of the last exposure, SP
agonist was injected intradermally into the exposed sites. Immediately after
injections, DNFB (185 µg) was applied to the injected sites. Fourteen days
later, a second dose of DNFB (185 µg) was painted on previously untreated
skin sites (dorsal). Ear challenge and the determination of ear swelling
responses are presented as described in the legend to Fig 1. Mean values
significantly lower than positive control: *p , 0.001.
Niizeki and Streilein, 1997). One way to detect UVR-dependent
tolerance is to expose mice first to hapten via UVR-treated
abdominal skin, and then to reimmunize the animals subsequently
with a sensitizing dose of hapten painted on untreated dorsal skin.
Failure of the mice to develop vigorous CH following the second
immunization is evidence that tolerance has been induced. In the
following experiments, panels of C3H/HeN mice received i.d.
injections of SP agonist (5 nmol) or PBS only into dry-shaved
abdominal skin after the last of four consecutive daily exposures of
acute, low-dose UVR. DNFB (185 µg in acetone) was then
painted within 30 min on the epicutaneous surface overlying the
injected site. Positive control mice received i.d. injections of PBS
without UVR exposures. Two weeks later, DNFB (185 µg) was
again applied to freshly shaved skin surface distant from the site
originally exposed to UVR. The pinnae of all mice, plus a negative
control panel, were challenged 5 d later with 15 µg DNFB in
acetone, and measured with an engineer’s micrometer 24 h later
as an indication of the development of CH. The results of a
representative experiment (of two) are presented in Fig 5. C3H/
HeN mice that first encountered DNFB via UVR-exposed skin
developed feeble CH when immunized subsequently with hapten
on normal skin, i.e., the mice had acquired tolerance. The group
of mice that first encountered DNFB via SP agonist-injected skin
after UVR, however, developed high intensity CH when compared
with positive control. These data indicate that SP can prevent
UVR-dependent tolerance.
SP agonist can reverse UVR-dependent tolerance In the
next series of experiments, we inquired whether SP agonist can
eliminate tolerance after it has been established by painting hapten
on UVR-exposed skin. To state the goal of this experiment in
query form: can SP agonist abrogate UVR-dependent tolerance if
the agonist is injected i.d. 30 min before the second application of
DNFB (185 µg), but 2 wk after these mice were exposed to four
doses of UVR followed immediately by epicutaneous DNFB
(185 µg). The results of a representative experiment (of two) are
presented in Fig 6. C3H/HeN mice that first encountered DNFB
via UVR-exposed skin developed feeble CH when immunized
subsequently with hapten on normal skin (Group 2); however, the
group of mice (Group 1) that first encountered DNFB via UVR-
exposed skin, and then re-encountered the same hapten through
skin treated with SP agonist 2 wk later developed intense CH,
comparable with unirradiated positive controls. These data indicate
that SP can reverse UVR-dependent tolerance by enhancing the
effects of the second exposure to hapten, and this is a different
consequence of SP activity from that which overcomes the local
effects of UVR on CH induction at the site of irradiation. The
ability of SP agonist to prevent tolerance induction after UVR
resembles the capacity of IL-12 to reverse UVR-dependent toler-
ance (Schwarz et al, 1996; Riemann et al, 1996).
DISCUSSION
Several lines of recent inquiry have led investigators to consider a
role for neuropeptides normally found in epidermal terminii of c-
type nerve fibers in cutaneous immunity of the CH type (Ansel
et al, 1996). Although Paul Langerhans originally proposed that
Langerhans cells themselves were components of the nervous system
(Langerhans, 1968), their origins from hematopoietic progenitors
has been clearly established (Frelinger et al, 1979; Katz et al,
1979). Granstein and colleagues reawakened interest to the neural
connectivity of Langerhans cells by demonstrating that c-type nerve
fiber terminii containing CGRP were present on the surfaces of
Langerhans cells in normal skin (Hosoi et al, 1993). More recently,
it has been reported that CGRP was able to inhibit CH induction
(Asahina et al, 1995), and that CGRP was released from c-type
fiber terminii in rat skin exposed to UVR (Benrath et al, 1995).
Most recently, Niizeki et al demonstrated that an antagonist of
CGRP can reverse the deleterious effects of acute, low-dose UVR
on CH induction (Niizeki et al, 1997). Because many nerve endings
contain both CGRP and SP, and because these neuropeptides often
display antagonist functional properties, it is important to know
the extent to which SP can modify cutaneous immunity. Several
laboratories have inquired recently into the possible role of SP on
induction and expression phases of CH (Ek and Theodorsson,
1990; Gutwald et al, 1991; Goebeler et al, 1994). The results of
the experiments, however, failed to prove a role for SP in the
induction phase of CH. Therefore, the results of the experiments
that form the basis of this report indicate definitive roles for SP
during CH induction in normal skin, and potential roles during
CH induction in UVR-exposed skin and in UVR-dependent
tolerance.
I.d. injections of a SP agonist augmented the intensity of CH
induction through the skin of normal mice. This positive effect
was observed when a high dose of sensitizing hapten (DNFB,
185 µg) was applied epicutaneously, but was not observed at much
lower sensitizing doses, often called optimal sensitizing doses
(Kurimoto and Streilein, 1993). Kurimoto and Streilein (1993)
provided strong circumstantial evidence several years ago that
optimal sensitizing doses of hapten induced CH primarily through
the actions of epidermal APC (Langerhans cells), whereas conven-
tional sensitizing doses induced CH primarily with the aid of
dermal APC. In fact, Bacci et al (1997) have recently reported that
conventional sensitizing doses are so toxic that there are virtually
no functionally competent Langerhans cells in the epidermis within
VOL. 112, NO. 4 APRIL 1999 SUBSTANCE P PROMOTES CUTANEOUS IMMUNITY 441
Figure 6. SP agonist reverses UVB-
induced tolerance. Abdominal skin of
C3H/HeN mice received exposure to
400 J UVR per m2 daily for four
consecutive days (Groups 1, 2). Immedi-
ately after the last exposure, DNFB
(185 µg) was applied at the exposed sites.
Fourteen days later, 5 nmol of SP agonist
(Groups 1, 3) or PBS (Groups 2, 4, 5) was
injected into previously untreated dorsal
skin sites. Within 30 min after these
injections, a second dose of DNFB (185 µg)
was painted on the injected sites. Ear
challenge and the determination of ear
swelling responses are presented as
described in the legend to Fig 1. Mean
values significantly lower than positive
control (Group 4): *p , 0.00001.
the first 6–12 h after hapten is applied at high dosage. This line of
reasoning leads us to postulate that SP enhances CH induction by
acting on dermal cells, rather than epidermal cells.
The ability of a neuropeptide of presumed epidermal origin to
have a primary mode of action on a dermal cell is not unprecedented.
Niizeki et al recently demonstrated that i.d. injection of CGRP
impaired CH induction by inducing dermal mast cells to release
TNF-α. These experiments were conducted with low (optimal)
sensitizing doses of hapten (doses that act primarily via epidermal
APC), suggesting that neuropeptides placed in the dermis can
diffuse into the epidermis and modify the functional properties of
Langerhans cells. To underscore this point, several reports from
our laboratory over the past 7 y have amply demonstrated that i.d.
injections into murine skin of cytokines (TNF-α, IL-10) and other
neuropeptides (α-MSH) can influence the form and function of
epideraml Langerhans cells as well as the ability of the injected skin
to support CH induction and tolerance (Vermeer and Streilein,
1990; Yoshikawa and Streilein, 1990; Kurimoto and Streilein, 1992;
Shimizu and Streilein, 1994a; Niizeki and Streilein, 1997). In the
aggregate these findings indicate that neuropeptides and cytokines
can diffuse readily across the dermal–epidermal junction and can
influence susceptible bone marrow-derived cells that participate in
induction and regulation of cutaneous immunity.
It is of considerable interest that SP agonist promoted CH
induction when hapten was painted on skin exposed to acute, low-
dose UVR. SP agonist joins several other agents that have been
similarly shown to enable hapten painted on UVR-exposed skin
to induce intense CH. The list of such agents includes anti-TNF-
α antibody, vitamin C, and IL-12 (Yoshikawa and Streilein, 1990;
Mu¨ller et al, 1995; Nakamura et al, 1997). The results of these
experiments do not indicate whether SP agonist acts in a unique
fashion to reverse the effects of UVR, or whether it acts through
one of the agents previously described. We doubt that the effects
of SP agonist are related to vitamin C because SP itself promotes
reactive oxygen intermediate formation from macrophages
(Hartung and Toyka, 1983; Murris-Espin et al, 1995), and vitamin
C is believed to prevent UVR damage by inhibiting oxygen radical
formation (Nakamura et al, 1997). Although SP resembles CGRP
in its capacity to selectively activate TNF-α production from mast
cells (Ansel et al, 1993), we favor the view that SP agonist-activated
APC are resistant to TNF-α. In fact, SP is reported to induce the
generation of several cytokines that have opposing effects to TNF-
α and IL-1 (Lotz et al, 1988; Laurenzi et al, 1990; Ansel et al, 1993;
Viac et al, 1996). Because SP agonist has been reported to induce
IL-12 production by lipopolysaccharide-treated macrophages
(Kincy-Cain and Bost, 1997), we currently favor the hypothesis
that SP agonist promotes CH induction after UVR by promoting
IL-12 production. This hypothesis is supported by the findings that
injection of IL-12 alone abolishes the deleterious effects of UVR
on CH induction (Schwarz et al, 1996), and that IL-12 supersedes
the ability of IL-10 to suppress sensitization (Mu¨ller et al, 1995).
The mechanism(s) by which SP agonist reverses UVR-dependent
tolerance are also of interest. TNF-α appears to play little if any
role in tolerance after UVR, whereas there is considerable evidence
to implicate IL-10 as the responsible tolerance-promoting cytokine
(Niizeki and Streilein, 1997). Because we have recently found that
dermal mast cells are the most important cutaneous source of
IL-10 after UVR exposure that leads to tolerance, SP agonist could
prevent tolerance by preventing mast cells from releasing IL-10.
Alternatively, SP agonist may restore the APC defect in UVR-
exposed skin, perhaps through IL-12, which would enable function-
ally enhanced hapten-bearing APC to supersede the skin-derived
tolerance-conferring stimulus that UVR creates on dermal cells
after UVR (Kurimoto et al, 1994).
The target cells upon which SP agonist acts in the dermis is
unclear. Dermal APC seem to express NK-1R, as do mast cells.
On the one hand, mast cells have the ability to produce TNF-α
(Ansel et al, 1993). Moreover, TNF-α released from dermal mast
cells is known to be a cytokine that impairs CH induction (Niizeki
et al, 1997). On the other hand, SP-activated dermal APC may be
resistant to TNF-α. This hypothesis is supported by our finding
that injection of SP agonist into skin after four consecutive daily
exposures of UVR rendered the skin resistant to the deleterious
effects of UVR. Mice treated in this way responded to epicutaneous
application of DNFB with intense CH (Fig 4).
The ability of SP agonist to reverse the deleterious effects of
UVR on cutaneous immunity presents a paradox. Terminii of
c-type nerve fibers in the epidermis contain both CGRP and SP
(reviewed in Ansel et al, 1996), and both are released following
UVR exposure (Benrath et al, 1995). Yet, CGRP appears to dictate
the immune outcome. As mentioned previously, CGRP plays a
leading role after UVR in causing mast cells to release TNF-α,
which is a primary mediator of the immune deficits observed
(Niizeki et al, 1997). As exogenous SP (SP agonist) reverses these
UVR-dependent immune deficits, why doesn’t SP neutralize the
effects of CGRP when both are released by UVR exposure? The
reason may rest with the stability of these two neuropeptides.
Native SP has a very short half-life in vivo, presumably because it
is readily degraded by indigenous neuropeptidases (Matsas et al,
1984). CGRP is much more stable, as is the SP agonist we used
in our experiments. Thus, CGRP may dominate after UVR
exposure simply because SP is rapidly degraded and unable to
materially influence subsequent immune events. Most recently,
Scholzen et al (1998) demonstrated that CH was enhanced in
neuropeptidase knockout mice. It is noteworthy that this effect
could be abrogated by injections of a NK-1R-specific antagonist
(Scholzen et al, 1998). This result enables us to postulate that
enhancement of signals through NK-1R could enhance CH
response by blocking degradation of SP.
Our results provide evidence that SP agonist can induce the
functional enhancement of APC. This interpretation is further
supported by our finding that SP agonist reversed UVR-dependent
tolerance when injected i.d. 2 wk after the tolerance was induced.
At this time, tolerance is systemic, and hapten-specific regulatory
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T cells reside widely in lymph nodes and spleen. Yet an i.d.
injection of SP agonist followed by epicutaneous hapten induced
vigorous CH in mice previously exposed to UVR and hapten. It
is relevant that we demonstrated that SP agonist, in the dose
and route injected, had no systemic effect on hapten immunity.
Therefore, the finding that SP agonist abolishes established UVR-
dependent tolerance suggests that SP may be acting locally within
the skin as an ‘‘adjuvant’’, amplifying the immunogenic signal that
arises when hapten is painted epicutaneously. We suspect that
cutaneous APC may be energized by SP, which enables these cells
to become the mediators of the ‘‘adjuvant’’ effect. Our experiments
are designed to test this possibility.
Finally, our finding that SP agonist promotes CH induction
contrasts with the report that SP itself fails to enhance CH induction
(Gutwald et al, 1991). There are several possible explanations for
this discrepancy. SP can bind to a range of specific receptors
(NK-1R, NK-2R, NK-3R), whereas SP agonist binds only to
NK-1R (Hagan et al, 1989). These receptors may have competing
properties that would prevent SP from delivering the type of
unambiguous signal that SP agonist can give. Perhaps the binding
of SP agonist to NK-1R is more stable than that of native SP
(Hagan et al, 1989), which would enable the agonist to be a more
effective ligand. Finally, SP has a much shorter half-life in vivo than
the SP agonist because the latter is resistant to neuropeptidases
(Matsas et al, 1984). This may enable the agonist to be a more
effective stimulator through time.
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